Per user reports across r/Nootropics, r/ADHD, r/AskDocs:

Onset (Intuniv ER 1-4 mg evening dose, typical):

• 1-2 hr: noticeable calm, reduced "buzz," BP and HR drop slightly
• 2-4 hr: sedation peaks; many users dose at night because of this
• Steady-state (after 1-2 weeks): tolerance to sedation builds for some; for others it persists
• Subjective: "calmer, quieter mind, less reactive, slightly slowed-down feeling"

Peak / steady-state effects:

• Sedation — the dominant effect for most healthy users. Drowsiness, sometimes daytime tiredness. ADHD literature: 36% somnolence, 20% fatigue, 28% headache.
• Reduced anxiety / hyperarousal — quieter inner monologue, less rumination, less reactive to stress.
• Calm, slightly disengaged — some describe it as "the volume turned down," similar to clonidine but less heavy-blanket.
• Reduced impulsivity — useful in ADHD context; for healthy users this can read as "harder to initiate / less spontaneous."
• No euphoria, no clear cognitive lift in healthy users — most healthy reports describe "duller, slower, calmer" rather than "sharper."
• Cold extremities possible (peripheral α2 effect).
• Lower BP, slower HR — measurable on a cuff and on Oura.

Taper / discontinuation:

• Half-life is long (~17 hr) — single-day cessation is mild, but abrupt cessation after weeks of daily use can produce rebound hypertension and tachycardia, sometimes severe (well-documented for clonidine, less but real for guanfacine). Always taper.

The vibe vs Dylan's goal:

• Dylan's V5 stack is built around modafinil + bromantane + Adamax/Semax — an alertness, dopamine, and PFC-trophic axis aimed at sustained 6-12 hr cognitive output.
• Guanfacine is the opposite vector — sedating, BP-lowering, slowing.
• The only context where this would help Dylan is as an evening wind-down / sleep-onset adjunct, but he already has a working sleep approach (apigenin + tryptophan + magnesium + sleep mask + chronotype migration), and adding guanfacine for that purpose has worse risk/reward than the existing tools.

• Tolerance to sedation: Some develops over 2-4 weeks for some users; persists in others.
• Tolerance to BP/HR effect: Limited; the antihypertensive effect persists with chronic use.
• Tolerance to ADHD efficacy: Limited; chronic efficacy holds across long-term studies (~1 year extension data).
• Recommended cycle: None — ADHD is a chronic indication; either you're on it long-term or you're not.
• Reset: Not relevant.

Synergistic with

• Stimulants (amphetamine, methylphenidate) for ADHD adjunct use — orthogonal mechanism, on-label combination, useful for residual symptoms and stimulant-induced sleep disruption / impulsivity rebound. Not Dylan-relevant unless ADHD diagnosis.

Avoid stacking with

• Modafinil / armodafinil — directly opposite vectors (eugeroic vs sedative). For Dylan, this is the load-bearing reason guanfacine is wrong. Guanfacine would actively undercut modafinil's wakefulness signal.
• Other CNS depressants (alcohol, benzodiazepines, sleep meds) — additive sedation.
• Other antihypertensives (beta-blockers including propranolol, ACE inhibitors, ARBs, CCBs) — additive BP-lowering and bradycardia. Specifically: stacking guanfacine + propranolol = unwanted compounded bradycardia.
• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) — raise guanfacine exposure 2-3× → severe sedation/hypotension.
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) — cut exposure ~70% → loss of efficacy.
• MAOIs — theoretical risk of hypertensive crisis if MAOI is non-selective; with selegiline at MAO-B-selective doses (Dylan's V5 conditional), risk is minimal but not zero.
• Tricyclic antidepressants — can blunt the antihypertensive effect.

Neutral / safe co-administration

• Most peptides (BPC-157, TB-500, Cerebrolysin, etc.) — no known interaction
• Most racetams — fine
• Vitamin/mineral supplements — fine
• L-theanine, magnesium, glycine — fine but mildly additive on calm/sedation

Guanfacine's CYP profile:

• Substrate: CYP3A4 (primary) — exposure markedly affected by CYP3A4 modulators
• Inhibitor: None clinically significant
• Inducer: None clinically significant

Specific Dylan-relevant flags:

• Modafinil/armodafinil are weak CYP3A4 inducers — would modestly reduce guanfacine exposure (probably 20-30%). Net pharmacodynamic effect: stimulant-like vs sedative still antagonistic regardless.
• No interaction with peptides, racetams, NAC, citicoline, fish oil, magnesium, l-theanine, rhodiola, curcumin — Dylan's V4 stack is interaction-clean with guanfacine in principle, but the pharmacodynamic opposition to modafinil is the real blocker.

Contraceptives, statins, other common Rx: No major interactions of note for Dylan.

• CYP3A4 polymorphism: *22 allele (~5% Caucasians) → reduced enzyme activity → higher guanfacine exposure. Action item if 23andMe results show *22.
• CYP3A5 expressors (~10-30% depending on ethnicity) — not typical Caucasian, but those with CYP3A5*1/*1 metabolize guanfacine somewhat faster.
• ADRA2A polymorphisms (the receptor itself) — some variants associated with differential response to α2A agonists in ADHD; not yet clinically actionable.
• For Dylan (Nordic/British ancestry): Expected to be a normal CYP3A4 metabolizer; standard exposure expected.

Strategic note for Dylan: Sourcing is trivial if indication is real. No reason to acquire absent ADHD diagnosis. Telehealth ADHD evaluation in 2026 is more rigorous post-Cerebral fallout — not a fast lane to off-label use.

Baseline (before starting)

• Resting HR (Oura) — 14-day average
• Resting BP cuff — 3-reading average; supine + standing for orthostatic delta
• Standing BP at 1 min and 3 min after rising — orthostatic baseline
• ECG — for chronic dosing (advisable in ADHD initiation per peds guidelines, less rigorous in adults)

During use

• HR (Oura) — expect 5-15 bpm drop
• BP (cuff) — expect 5-10 mmHg drop systolic; watch for >20 mmHg orthostatic delta
• Daytime alertness rating — 1-10 daily
• Cognitive output (subjective + tracked metrics) — sales-call output, code-output, words-written for a baseline

Discontinuation

• BP daily for 2 weeks post-cessation — watch for rebound
• HR daily for 2 weeks — watch for rebound tachycardia